TSX runs higher on rate cut expectations
MVM Partners, LLC, a significant shareholder in Paragon 28 , Inc. (NYSE:FNA), has reported the sale of 1,374,635 shares of the company’s common stock over three days, according to a recent SEC filing. The transactions, which took place from March 4 to March 6, 2025, were executed at prices ranging between $12.99 and $13.02 per share, generating a total of approximately $17.88 million. The sales occurred as the stock trades near its 52-week high of $13.13, having surged approximately 78% over the past six months. InvestingPro analysis indicates the stock is currently in overbought territory.
Following these transactions, MVM Partners now holds 8,854,883 shares of Paragon 28, which has a market capitalization of $1.09 billion. The shares were sold in multiple transactions, and the prices reported are weighted averages. The company maintains strong liquidity with a current ratio of 3.5, indicating robust short-term financial health. For deeper insights into Paragon 28’s technical indicators and valuation metrics, check out the comprehensive analysis available on InvestingPro.
MVM Partners, based in Boston, Massachusetts, is a ten percent owner of Paragon 28, a company specializing in surgical and medical instruments. The sales were executed indirectly through various MVM entities, as noted in the filing.
In other recent news, Paragon 28, Inc. has announced preliminary unaudited financial results for the fourth quarter and full year of 2024. The company expects fourth-quarter revenue to be between $71.5 million and $71.8 million, marking an 18% to 18.5% increase over the same period last year. For the full year, revenue is projected to range from $255.9 million to $256.2 million, reflecting an 18.2% to 18.4% growth compared to 2023. In a significant corporate development, Zimmer Biomet Holdings (NYSE:ZBH), Inc. has entered into an agreement to acquire Paragon 28 for approximately $1.2 billion, with shareholders receiving $13 per share and a contingent value right potentially adding another $1 per share. Analysts at Stephens and Needham have downgraded Paragon 28’s stock ratings following the acquisition announcement, with Stephens moving from Overweight to Equal Weight and Needham from Buy to Hold. Despite the downgrades, Needham analysts had previously maintained a Buy rating based on positive revenue estimates, highlighting a preannouncement of fourth-quarter revenue that exceeded consensus estimates. The acquisition by Zimmer Biomet, which offers a premium over Paragon 28’s recent stock price, is seen as a strategic move to enhance its position in the orthopedic devices sector. Paragon 28’s CEO, Albert DaCosta, noted 2024 as a transformative year for the company, with optimism for continued growth into 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.